Drug delivery

Generic Drugs Global Market Report 2023: Growing Demand for Low-Cost Drugs Bolster Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 3, 2023
Health, Pharmaceutical, Molecule, COPD, Urbanization, Patent, Insurance, Asthma, Drug delivery, Prevalence, Diabetes, Marketing, Arthritis, Fingolimod, Cetuximab, Ageing, Cancer, Head, Research, Tobacco, Multiple sclerosis, Bristol Myers Squibb, USD, Competition, Hypertension, Market, Malignancy, Death, US, Chronic Respiratory Disease, National Health, Chronic condition, Patient, Application, Developed country, National Health Interview Survey, Plasma protein binding, Form, Conditional sentence, Growth, WHO, FDA, Notifiable disease, Safety, Generic drug, Pharmaceutical industry

The Generic Drugs market is expected to continue growing in the coming years, driven by factors such as the increasing prevalence of chronic diseases, expiration of patent drugs, growing demand for low-cost drugs, and easy accessibility and supportive governments for allowing generic drugs in the market.

Key Points: 
  • The Generic Drugs market is expected to continue growing in the coming years, driven by factors such as the increasing prevalence of chronic diseases, expiration of patent drugs, growing demand for low-cost drugs, and easy accessibility and supportive governments for allowing generic drugs in the market.
  • Advancements in generic drugs have also contributed to the growth of the Generic Drugs market.
  • One of the biggest challenges the global generic drugs market is facing is ensuring the quality of generic drugs is the same as branded drugs.
  • This has led to increased demand for generic drugs in these regions, which has, in turn, contributed to the growth of the global generic drugs market.

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Drug delivery, OASIS, ARVO, Association for Research in Vision and Ophthalmology, Suprachoroidal drug delivery, Macular degeneration, AMD, Pharming, Safety, Eye, Clearside, Publication, Persistent, Pathology, Integrin, Annual general meeting, Toxicology, Triamcinolone, Macular edema, Poster, Patient, Research, Visual acuity, Axitinib, The Association, Pharmacology, SCS, Vaccine, Pharmaceutical industry, Ophthalmology

“In the studies presented, SCS delivery of small molecule suspensions offered targeted, compartmentalized, and durable drug delivery to the chorioretina.

Key Points: 
  • “In the studies presented, SCS delivery of small molecule suspensions offered targeted, compartmentalized, and durable drug delivery to the chorioretina.
  • Integrins play a major role in diverse biologic as well as pathologic processes such as cell adhesion/migration, angiogenesis, and immune responsiveness.
  • In the study, SCS delivery of an integrin inhibitor was well tolerated and offered targeted, compartmentalized, and durable drug delivery to the chorioretina.
  • Clearside’s medical meeting presentations can be accessed on the Company’s Publications and Presentations page.

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Retrieved on: 
Tuesday, April 18, 2023
Shareholder, Arthur D. Little, Drug delivery, Senior, Alnylam Pharmaceuticals, Sofinnova, Arthur, Rotation, Annual, Supervisory board, AG, AGM, Mergers & Acquisitions, MBA, Almirall, RNA, Doctor of Philosophy, EDT, Bachelor of Science, Ophthalmology, Nyenrode Business University, Novartis, Incident management team, INSEAD, Janssen Pharmaceuticals, Baxter International, Senior management, Mergers and acquisitions, Therapy, ProQR, London School of Business and Finance, BD, Pharmaceutical industry, Management, Biochemistry, Sanofi, Galápagos Islands

Shareholders that wish to attend should register as described in the notice and agenda.

Key Points: 
  • Shareholders that wish to attend should register as described in the notice and agenda.
  • As part of the AGM, the Company highlights the following Supervisory Board updates:
    Begoña Carreño, PhD, is nominated for election to the Supervisory Board.
  • Earlier in her career, Ms. Heggie held increasingly senior positions in the commercial organizations at Janssen Pharmaceuticals and Baxter Healthcare.
  • Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, has indicated his planned rotation off the ProQR Supervisory Board at the upcoming AGM.

Kindeva Drug Delivery Announces the Appointment of David Stevens as Global CCO

Retrieved on: 
Wednesday, April 5, 2023
Science, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Other Health, GMP, Charles River Laboratories, University, Drug delivery, Marketing, MBA, Research, Multimedia, CCO, CDMO, Patient, Recipharm, Growth, AMRI, Fine chemical, Kindeva

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO).

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO).
  • Stevens will spearhead the commercial, business development, and research and development activities for the business to ensure continued growth, expansion, and innovation.
  • View the full release here: https://www.businesswire.com/news/home/20230405005276/en/
    David Stevens has been appointed global chief commercial officer for Kindeva Drug Delivery.
  • “The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges,” Stevens said.

Vect-Horus Appoints Dr Jean-Manuel Péan as Chief Scientific Officer

Retrieved on: 
Monday, April 3, 2023
Health, Medical Devices, Health Technology, Other Health, Radiology, Pharmaceutical, Biotechnology, D.A.V. College Managing Committee, University, Jean-Manuel Thetis, Publication, Drug delivery, Pharmacy, Doctor of Philosophy, Pharmaceutical industry

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.

Key Points: 
  • VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.
  • In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
  • Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our Chief Scientific Officer as he brings over 20 years of significant experience in the pharmaceutical industry.
  • Dr Péan obtained his PhD in Pharmaceutical Sciences from Paris XI University.

SRI International Appoints Kathlynn Brown to Biosciences Division President

Retrieved on: 
Tuesday, January 31, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medicine, Government, Molecular biology, Moses Austin, University of Texas Southwestern Medical Center, Damon Runyon, Biochemistry, Biomedical Research, Drug delivery, Doctor of Philosophy, University, San Francisco, Lung cancer, FOX, Communication, American Chemical Society, SRI International, Management, SRI, List of life sciences

SRI International , an independent nonprofit research institute behind countless cutting-edge technological advances, today announced the promotion of Kathlynn Brown to President of its Biosciences Division.

Key Points: 
  • SRI International , an independent nonprofit research institute behind countless cutting-edge technological advances, today announced the promotion of Kathlynn Brown to President of its Biosciences Division.
  • In her eight-year tenure at SRI International, she has helped the organization double down on its impacts in these fields.
  • “I am thrilled that Kathlynn will become the new president of Biosciences division,” said David Parekh, CEO of SRI.
  • Out of a tremendously talented pool of potential candidates, Kathlynn’s scientific background and her work with both government-funded clients and leading pharmaceutical companies have made her the perfect choice for this important role.”
    “For nearly a decade, I have had the privilege of working alongside creative and dedicated scientists at SRI International as we pave the way in bioscience research,” said Kathlynn Brown, incoming President of SRI International biosciences division.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Technology, Other Health, Health, General Health, Other Science, Research, Infectious Diseases, Nanotechnology, Genetics, Science, Infection, Severe acute respiratory syndrome coronavirus 2, Transdermal, UCPH Department of Biology, Editorial board, University of Washington Department of Bioengineering, Hepatitis B, NIH, United States Air Force Scientific Advisory Board, CRISPR, Associate, ERC, University, CRS, Internal medicine, Stanford University, Engineer, Degenerative disease, Chair, Pharmaceutics, RNA, Molecular Pharmaceutics, New York Genome Center, Scientist, Ludwig Maximilian University of Munich, Doctor of Philosophy, SNF, MIT, Nervous system, Physiology, BS, Y combinator, Computational linguistics, SAB, MS, PRDS, Drug resistance, JCR, Drug delivery, MIT Department of Brain and Cognitive Sciences, Cognitive science, Medical device, Pharmaceutical industry, Brain, Biology, Carver, List of life sciences, Neuroscience, New York University

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).
  • Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB.
  • Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.
    “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver.
  • Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.

No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pain Therapy Implants

Retrieved on: 
Tuesday, December 13, 2022
Medical Devices, Health, Surgery, Managed Care, Pharmaceutical, Biotechnology, Therapy, Nutrition, Chemistry, Physician, Development, Polymer, Biopolymer, Pain, Hospital, Drug delivery, Research, Patient, Knee, Analgesic, Spinal cord, EVC, Lightstone, Health care, Evonik Industries, Investment, EBITDA, Foundry, Brain, Pain management, Material, Oxycodone, Morphine, Risk, Fine chemical, Dentistry, San Francisco Bay Area

Biodegradable polymers from Evonik are the key to the success of this new type of pain therapy: they ensure that the active ingredients are delivered over a longer period.

Key Points: 
  • Biodegradable polymers from Evonik are the key to the success of this new type of pain therapy: they ensure that the active ingredients are delivered over a longer period.
  • "Our products may provide patients with pain relief exactly when they need it most - for weeks instead of days.
  • This would significantly improve and accelerate the recovery process," says Adam Gridley, Chief Executive Officer (CEO) of Allay Therapeutics.
  • Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.

Kindeva and Meridian Combine: Create Leading Drug-Device Combination Product CDMO

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, 3M, Inhalation, Pfizer, CDMO, JPMorgan Chase, Chase Bank, Health technology, Drug delivery, Research, NYSE, Kirkland & Ellis, Multimedia, Administration, PFE, Meridian Medical Technologies Inc., Pharmaceutical industry, Meridian, Kindeva

Kindeva Drug Delivery (Kindeva) and Meridian Medical Technologies (Meridian) announced today the completion of the transaction to combine the two companies.

Key Points: 
  • Kindeva Drug Delivery (Kindeva) and Meridian Medical Technologies (Meridian) announced today the completion of the transaction to combine the two companies.
  • The combination has created a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products.
  • The combination will operate under the Kindeva name, with Meridian operating as, Meridian Medical Technologies, a Kindeva Company.
  • The combination of Kindeva and Meridian creates a clear market leader in the drug-device CDMO sector.

Growth Opportunities in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Biotechnology, Pharmaceutical, Health, Therapy, Regenerative medicine, Disease management, Tissue engineering, Environment, Drug discovery, Drug delivery, Wellness, Biomarker, DNA, Synthetic biology, Pain, Health, Nanomedicine, Genetic engineering, Ministry of Health & Wellness, Innovation, Antibiotics, Pharmaceutical industry

The "Growth Opportunities in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery" report has been added to ResearchAndMarkets.com's offering.
  • Engineered synthetic cells, microbes for antibiotic production and cell-free biosensors for environment applications are some of the other synbio related innovations covered in this issue.
  • The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
  • Innovations in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery